# Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

> **NCT02114502** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** SAHA
- **DRUG:** Gemcitabine
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **PROCEDURE:** Stem Cell Transplant (SCT)
- **DRUG:** Palifermin
- **DRUG:** Dexamethasone
- **DRUG:** Caphosol
- **DRUG:** Glutamine
- **DRUG:** Pyridoxine

## Key facts

- **NCT ID:** NCT02114502
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-09
- **Primary completion:** 2018-09
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02114502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02114502, "Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02114502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*